Download - WHOCC

More documents

Recommendations

Info

Preface The Anatomical Therapeutic Chemical classification system for veterinary medicinal products, ATCvet, has been developed by the Nordic Council on Medicines (NLN) in collaboration with the NLN’s ATCvet working group, consisting of experts from the Nordic countries. The system is based on the same main principles as the ATC classification system for substances used in human medicine. The ATCvet system has been developed in association with the WHO Collaborating Centre for Drug Statistics Methodology in Oslo. The WHO Collaborating Centre for Drug Statistics Methodology is responsible for developing and maintaining the ATC system, and has since January 2001, also had the responsibility for the ATCvet classification system. The first edition of the Guidelines on ATCvet classification was published in 1992 followed by revised editions in 1995 and in 1999. These guidelines attracted international interest and have also been used to classify veterinary medicinal products outside, as well as inside, the Nordic region. The ATCvet classification system will be continuously revised in line with the ATC system and in response to the expanding range of preparations available in the field of veterinary medicine. Details of the classification codes assigned to all the substances classified can be found in the ATCvet Index, which is issued annually. The Guidelines on ATCvet classification, which also are revised annually, are needed to explain and provide comments on the classifications recommended. Copies of the Guidelines and the Index can be ordered from the WHO Collaborating Centre for Drug Statistics Methodology. The ATCvet Index, as well as further information about the ATCvet classification system, is also available on the Internet, at the website of the WHO Collaborating Centre, http://www.whocc.no.
The ATCvet Working Group has at present the following members: Anders Eriksson Minerva Foundation for Medical Research, Finland Beat Gassner Swissmedic, Switzerland Kari Grave Norwegian School of Veterinary Science, Norway Vibeke Frøkjær Jensen Danish Institute of Food and Veterinary Research, Denmark Cristina Muñoz Madero Spanish Agency of Medicines and Medical Devices, Spain Stephan Steuber BVL (Bundesamt für Verbraucherschutz und Lebensmittelsicherheit), Germany WHO Collaborating Centre for Drug Statistics Methodology Oslo, January 2011 Christian Berg, MSc Pharm/MPH Hege Salvesen Blix, MSC Pharm/PhD Irene Litleskare, MSc Pharm Hanne Strøm, MSc Pharm Tove Granum, secretary WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health
Page 2 and 3: Guidelines for ATCvet classificatio
Page 4 and 5: Guidelines for ATCvet classificatio
Page 8 and 9: Contents 1 Introduction to the ATCv
Page 10: QN - Nervous system................
Page 13 and 14: 1.3 Relationship between the ATCvet
Page 15 and 16: Classification according to the mai
Page 17 and 18: 2.2 Classification of plain prepara
Page 19 and 20: - Proposed ATCvet classification, w
Page 22 and 23: QA ALIMENTARY TRACT AND METABOLISM
Page 24 and 25: QA ALIMENTARY TRACT AND METABOLISM
Page 26 and 27: QA02B DRUGS FOR PEPTIC ULCER AND GA
Page 28 and 29: QA03D QA03DA QA03DB QA03DC ANTISPAS
Page 30 and 31: Combined packages comprising tablet
Page 32 and 33: QA07D QA07DA ANTIPROPULSIVES Antipr
Page 34 and 35: QA10BD QA10BF QA10BG QA10BH QA10BX
Page 36 and 37: QA11GB Ascorbic acid (vitamin C), c
Page 38 and 39: QA12CD QA12CE Fluoride Selenium Sod
Page 40 and 41: QB BLOOD AND BLOOD FORMING ORGANS Q
Page 42 and 43: QB02BC Local hemostatics Gauze, tam
Page 44 and 45: QB05C IRRIGATING SOLUTIONS Preparat
Page 46 and 47: QC CARDIOVASCULAR SYSTEM QC01 QC02
Page 48 and 49: QC CARDIOVASCULAR SYSTEM QC01 QC01A
Page 50 and 51: QC01D VASODILATORS USED IN CARDIAC
Page 52 and 53: QC02DC QC02DD QC02DG QC02K Pyrimidi
Page 54 and 55: QC03C HIGH-CEILING DIURETICS High-c
Page 56 and 57:
QC05C QC05CA QC05CX CAPILLARY STABI
Page 58 and 59:
QC08D QC08DA QC08DB SELECTIVE CALCI
Page 60 and 61:
QD DERMATOLOGICALS QD01 QD02 QD03 Q
Page 62 and 63:
QD DERMATOLOGICALS This main group
Page 64 and 65:
QD02BB Protectives against UV-radia
Page 66 and 67:
QD05BX Other drugs for keratoseborr
Page 68 and 69:
QD07C CORTICOSTEROIDS, COMBINATIONS
Page 70 and 71:
QD08AH Quinoline derivatives Chloro
Page 72 and 73:
QG GENITO URINARY SYSTEM AND SEX HO
Page 74 and 75:
QG01AA Antibiotics Combinations wit
Page 76 and 77:
QG02CB QG02CC Prolactine inhibitors
Page 78 and 79:
The group is subdivided according t
Page 80 and 81:
QG04B OTHER UROLOGICALS, INCL. ANTI
Page 82:
QG52 PRODUCTS FOR TEATS AND UDDER P
Page 85 and 86:
QH SYSTEMIC HORMONAL PREPARATIONS,
Page 87 and 88:
QH02 CORTICOSTEROIDS FOR SYSTEMIC U
Page 89 and 90:
QH05B QH05BA ANTI-PARATHYROID AGENT
Page 91 and 92:
QI09 QI10 QI11 Q120 IMMUNOLOGICALS
Page 93 and 94:
QI01 QI01A QI01AA QI01AB QI01AC QI0
Page 95 and 96:
QI01C QI01CA QI01CB QI01CC QI01CD Q
Page 97 and 98:
QI01E QI01EA QI01EB QI01EC QI01ED Q
Page 99 and 100:
QI01KV QI01KX Other inactivated vac
Page 101 and 102:
QI03AM QI03AN QI03AO QI03AP QI03AQ
Page 103 and 104:
QI05AH QI05AI QI05AJ Live and inact
Page 105 and 106:
QI07 QI07A QI07AA QI07AB QI07AC QI0
Page 107 and 108:
QI07X QI07XA QI07XB QI07XC QI07XD Q
Page 109 and 110:
QI08B HARE QI08X LEPORIDAE, OTHERS
Page 111 and 112:
QI10AR QI10AS QI10AU QI10AV QI10AX
Page 113 and 114:
QI20AD QI20AE QI20AF QI20AG QI20AH
Page 115 and 116:
QI20DD QI20DE QI20DF QI20DG QI20DH
Page 117 and 118:
QJ ANTIINFECTIVES FOR SYSTEMIC USE
Page 119 and 120:
QJ01D OTHER BETA-LACTAM ANTIBACTERI
Page 121 and 122:
QJ01FG Streptogramins The streptogr
Page 123 and 124:
QJ01XX Other antibacterials Fumagil
Page 125 and 126:
QJ05AH Neuraminidase inhibitors All
Page 127 and 128:
QJ51RB QJ51RC QJ51RD Amphenicols, c
Page 129 and 130:
QL ANTINEOPLASTIC AND IMMUNOMODULAT
Page 131 and 132:
QL02 ENDOCRINE THERAPY Only prepara
Page 134 and 135:
QM MUSCULO-SKELETAL SYSTEM QM01 QM0
Page 136 and 137:
QM01B QM01BA ANTIINFLAMMATORY/ANTIR
Page 138 and 139:
QM03BC Ethers, chemically close to
Page 140 and 141:
QN NERVOUS SYSTEM QN01 QN02 QN03 QN
Page 142 and 143:
QN01B ANESTHETICS, LOCAL Local anes
Page 144 and 145:
QN02AG Opioids in combination with
Page 146 and 147:
QN03AF QN03AG QN03AX Carboxamide de
Page 148 and 149:
QN05B ANXIOLYTICS Preparations used
Page 150 and 151:
Lithium, see QN05AN - Lithium. Comb
Page 152:
QN07C QN07CA ANTIVERTIGO PREPARATIO
Page 155 and 156:
QP ANTIPARASITIC PRODUCTS, INSECTIC
Page 157 and 158:
Optional subgroups should be used o
Page 159 and 160:
QP53BB Organophosphorous compounds
Page 161 and 162:
QR RESPIRATORY SYSTEM Preparations
Page 163 and 164:
QR03 QR03A DRUGS FOR OBSTRUCTIVE AI
Page 165 and 166:
Preparations which contain small am
Page 167 and 168:
QR06AE Piperazine derivatives Cinna
Page 169 and 170:
QS SENSORY ORGANS Preparations for
Page 171 and 172:
QS01E ANTIGLAUCOMA PREPARATIONS AND
Page 173 and 174:
QS01KA Viscoelastic substances Hyal
Page 175 and 176:
QS03 OPHTHALMOLOGICAL AND OTOLOGICA
Page 177 and 178:
QV VARIOUS This group is the most h
Page 179 and 180:
QV04CC Tests for bile duct patency
Page 181 and 182:
QV07AC Blood transfusion, auxiliary
Page 183 and 184:
QV09A CENTRAL NERVOUS SYSTEM This g
Page 185 and 186:
QV09G CARDIOVASCULAR SYSTEM This gr
Page 187 and 188:
QV10X OTHER THERAPEUTIC RADIOPHARMA
Page 190 and 191:
WHO COLLABORATING CENTRE FOR DRUG S
Page 192:
ANNEX II
Page 195:
ORDER FORM - ATCvet PUBLICATIONS Pa
show all

Download - WHOCC

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?